JP2019524089A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019524089A5 JP2019524089A5 JP2019500420A JP2019500420A JP2019524089A5 JP 2019524089 A5 JP2019524089 A5 JP 2019524089A5 JP 2019500420 A JP2019500420 A JP 2019500420A JP 2019500420 A JP2019500420 A JP 2019500420A JP 2019524089 A5 JP2019524089 A5 JP 2019524089A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- once
- composition according
- days
- week
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 29
- 102100022641 Coagulation factor IX Human genes 0.000 claims 14
- 108010076282 Factor IX Proteins 0.000 claims 13
- 229960004222 factor ix Drugs 0.000 claims 13
- 230000000694 effects Effects 0.000 claims 6
- 108020001507 fusion proteins Proteins 0.000 claims 5
- 102000037865 fusion proteins Human genes 0.000 claims 5
- 230000036470 plasma concentration Effects 0.000 claims 5
- 102000008100 Human Serum Albumin Human genes 0.000 claims 2
- 108091006905 Human Serum Albumin Proteins 0.000 claims 2
- 108091005804 Peptidases Proteins 0.000 claims 2
- 239000004365 Protease Substances 0.000 claims 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 2
- 108010000499 Thromboplastin Proteins 0.000 claims 2
- 102000002262 Thromboplastin Human genes 0.000 claims 2
- 230000015271 coagulation Effects 0.000 claims 2
- 238000005345 coagulation Methods 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 208000032843 Hemorrhage Diseases 0.000 claims 1
- 230000000740 bleeding effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000009429 hemophilia B Diseases 0.000 claims 1
- 229960000027 human factor ix Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662359745P | 2016-07-08 | 2016-07-08 | |
| US62/359,745 | 2016-07-08 | ||
| PCT/EP2017/067127 WO2018007601A1 (en) | 2016-07-08 | 2017-07-07 | Subcutaneous administration of long-acting factor ix in humans |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019524089A JP2019524089A (ja) | 2019-09-05 |
| JP2019524089A5 true JP2019524089A5 (enExample) | 2020-07-27 |
| JP6971301B2 JP6971301B2 (ja) | 2021-11-24 |
Family
ID=59388044
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019500420A Active JP6971301B2 (ja) | 2016-07-08 | 2017-07-07 | ヒトにおける長時間作用性第ｉｘ因子の皮下投与 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20200093901A1 (enExample) |
| EP (2) | EP3481416B1 (enExample) |
| JP (1) | JP6971301B2 (enExample) |
| KR (1) | KR102446476B1 (enExample) |
| CN (1) | CN109843319A (enExample) |
| AU (1) | AU2017294555B2 (enExample) |
| CA (1) | CA3029887A1 (enExample) |
| DK (1) | DK3481416T3 (enExample) |
| ES (1) | ES2832648T3 (enExample) |
| PL (1) | PL3481416T3 (enExample) |
| WO (1) | WO2018007601A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4362971A1 (en) * | 2021-07-01 | 2024-05-08 | CSL Behring Lengnau AG | Factor ix subcutaneous administration with enhanced safety |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL113010A (en) | 1994-03-31 | 1999-10-28 | Pharmacia & Upjohn Ab | Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration |
| CA2405550A1 (en) * | 2000-04-12 | 2001-10-25 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US7939632B2 (en) | 2006-06-14 | 2011-05-10 | Csl Behring Gmbh | Proteolytically cleavable fusion proteins with high molar specific activity |
| CN103140237A (zh) | 2010-07-09 | 2013-06-05 | 比奥根艾迪克依蒙菲利亚公司 | 因子ix多肽及其使用方法 |
| TW201427685A (zh) * | 2012-09-25 | 2014-07-16 | Biogen Idec Inc | Ｆｉｘ多肽的應用 |
| EP3082848B1 (en) * | 2013-12-06 | 2023-10-18 | Bioverativ Therapeutics Inc. | Population pharmacokinetics tools and uses thereof |
| CA2934081A1 (en) * | 2013-12-23 | 2015-07-02 | Csl Limited | Fusion proteins comprising factor ix for prophylactic treatment of hemophilia and methods thereof |
-
2017
- 2017-07-07 EP EP17742959.4A patent/EP3481416B1/en active Active
- 2017-07-07 ES ES17742959T patent/ES2832648T3/es active Active
- 2017-07-07 CA CA3029887A patent/CA3029887A1/en active Pending
- 2017-07-07 DK DK17742959.4T patent/DK3481416T3/da active
- 2017-07-07 CN CN201780042142.6A patent/CN109843319A/zh active Pending
- 2017-07-07 KR KR1020197003706A patent/KR102446476B1/ko active Active
- 2017-07-07 EP EP20165521.4A patent/EP3733199A1/en not_active Withdrawn
- 2017-07-07 AU AU2017294555A patent/AU2017294555B2/en not_active Ceased
- 2017-07-07 JP JP2019500420A patent/JP6971301B2/ja active Active
- 2017-07-07 PL PL17742959.4T patent/PL3481416T3/pl unknown
- 2017-07-07 US US16/315,348 patent/US20200093901A1/en not_active Abandoned
- 2017-07-07 WO PCT/EP2017/067127 patent/WO2018007601A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017529326A5 (enExample) | ||
| JP2019194251A5 (enExample) | ||
| JP2016514132A5 (enExample) | ||
| JP2018522563A5 (enExample) | ||
| JP2015518818A5 (enExample) | ||
| JP2014534265A5 (enExample) | ||
| NZ608502A (en) | Polypeptides that bind to human complement component c5 | |
| MX2017012506A (es) | Composicion farmaceutica para la prevencion y tratamiento de enfermedades del ojo que contiene, como ingrediente activo, una proteina de fusion en la cual el peptido que penetra el tejido y la preparacion del factor de crecimiento endotelial antivascular se fusionan. | |
| JP2014516088A5 (enExample) | ||
| FI3511004T3 (fi) | Yhdistelmävalmisteita syövän hoitoon | |
| JP2015512927A5 (enExample) | ||
| JP2021001184A (ja) | ペグ化インターフェロンのための投薬計画 | |
| ZA202210024B (en) | Pharmaceutical composition for cancer treatment comprising fusion protein including il-2 protein and cd80 protein and anticancer drug | |
| RU2016129911A (ru) | Слитые белки, содержащие фактор ix, для профилактического лечения больных гемофилией и способы его осуществления | |
| JP2012524725A5 (enExample) | ||
| JP2019524089A5 (enExample) | ||
| Schulte | Challenges for new haemophilia products from a manufacturer’s perspective | |
| Ragni | Novel alternate hemostatic agents for patients with inhibitors: beyond bypass therapy | |
| US20200172587A1 (en) | Hydrochloride salts of c5a receptor agonist peptides | |
| US20200390845A1 (en) | Pharmaceutical formulations of c1 esterase inhibitor | |
| JP2019519466A5 (enExample) | ||
| RU2018132694A (ru) | Фармацевтическая композиция, включающая рекомбинантный гормон роста человека для лечения дефицита гормона роста | |
| JP2012529423A5 (enExample) | ||
| JP2020525498A5 (enExample) | ||
| Goubran et al. | New monoclonal/bi-specific antibodies: reshaping transfusion medicine beyond replacement |